Therapeutic effect of low molecular weight heparin combined with Doc-etaxel for second-line treatment of advanced non-small cell lung cancer with driver gene-negative
Therapeutic effect of low molecular weight heparin combined with Doc-etaxel for second-line treatment of advanced non-small cell lung cancer with driver gene-negative
Objective To investigate the clinical observation of low molecular weight heparin(LMWH)combined with Doc-etaxel in second-line treatment of advanced non-small cell lung cancer(NSCLC)with negative driver genes.Methods A to-tal of 100 patients with advanced NSCLC who met the criteria and were admitted to Yantai Shan Hospital from October 2017 to September 2020 were selected as study objects,and they were divided into study group and control group according to the random number table method,with 50 cases in each group.The study group was treated with Docetaxel chemotherapy com-bined with LMWH.The control group was treated with Docetaxel monotherapy until disease progression or adverse reactions became intolerable.The therapeutic effect,changes of coagulation function and adverse reactions were compared between the two groups.Results There was no significant difference in the objective remission rate between the two groups after 2 cycles of treatment(P＞0.05).After treatment,the disease control rate of the study group was higher than that of the control group,and the difference was statistically significant(P＜0.05).After treatment,the D-dimer and fibrinogen(FIB)in the study group were lower than those in the control group,and the differences were statistically significant(P＜0.05).The inci-dence of deep vein thrombosis in the study group was lower than that in the control group,and the difference was statistically significant(P＜0.05).There were no significant differences in the adverse reactions between the two groups(P＞0.05).Conclusion LMWH combined with Docetaxel for second-line treatment of driver gene-negative advanced NSCLC good short-term efficacy,can improve the short-term disease control rate,improve coagulation function,reduce the occurrence of venous thrombosis.
维普
万方数据